HRP20192174T1 - Kombinirani farmaceutski pripravak - Google Patents

Kombinirani farmaceutski pripravak Download PDF

Info

Publication number
HRP20192174T1
HRP20192174T1 HRP20192174TT HRP20192174T HRP20192174T1 HR P20192174 T1 HRP20192174 T1 HR P20192174T1 HR P20192174T T HRP20192174T T HR P20192174TT HR P20192174 T HRP20192174 T HR P20192174T HR P20192174 T1 HRP20192174 T1 HR P20192174T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
antibody
seq
amino acid
acid sequence
Prior art date
Application number
HRP20192174TT
Other languages
English (en)
Inventor
David Bechard
Nathalie CHAPUT
Mélanie DESBOIS
Original Assignee
Cytune Pharma
Institut Gustave Roussy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48951300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20192174(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytune Pharma, Institut Gustave Roussy filed Critical Cytune Pharma
Publication of HRP20192174T1 publication Critical patent/HRP20192174T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)

Claims (12)

1. Kombinirani farmaceutski pripravak koji sadrži: a) konjugat koji sadrži (i) polipeptid koji sadrži aminokiselinsku sekvencu interleukina 15 ili njegovih derivata koji imaju najmanje 10% aktivnosti ljudskog IL-15 na indukciju proliferacije stanice kit225, i (ii) polipeptid koji sadrži aminokiselinski slijed suši domene IL-15Rα ili njegovih derivata koji imaju najmanje 10% aktivnosti vezanja suši domene ljudskog IL-15Rα na humani IL-15, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid; i b) antitijelo koje antagonizira imunološki put uključeno u inhibiciju aktivacije T stanice, ili njegov fragment koji može reagirati s istim antigenom kao njegovo odgovarajuće antitijelo, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid, pri čemu je spomenuto antitijelo antagonist PD-1/PD-L1/PD-L2, pri čemu se spomenuto antitijelo antagonizira bilo vezanjem PD-1 receptora ili vezanjem PD-L1 ili PD-L2 liganda; pri čemu navedeni konjugat i njegovo antitijelo ili fragment nisu povezani.
2. Farmaceutski pripravak za uporabu u liječenju raka kod subjekta koji sadrži (A) konjugat koji sadrži (i) polipeptid koji sadrži aminokiselinsku sekvencu interleukina 15 ili njegovih derivata koji imaju najmanje 10% aktivnosti ljudskog IL-15 na indukciju proliferacije stanice kit225, i (ii) polipeptid koji sadrži aminokiselinski slijed suši domene IL-15Rα ili njegovih derivata koja ima najmanje 10% aktivnosti vezivanja suši domene ljudskog IL-15Rα na humani IL-15, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid, pri čemu se uporaba sastoji istovremeno, odvojeno ili uzastopno davanje (a) navedenog lijeka pripravka i (b) antitijelo koje antagonizira imunološki put uključeno u inhibiciju aktiviranja T stanica, ili njegov fragment koji može reagirati s istim antigenom nego njegovo odgovarajuće antitijelo, polinukleotidno kodiranje prema tome, ili vektor koji sadrži takav polinukleotid, ili (B) antitijelo koje antagonizira imunološki put uključeno u inhibiciju aktivacije T stanice, ili njegov fragment koji je sposoban reagirati s istim antigenom kao njegov kolega s antitijelom, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid, pri čemu se upotreba sastoji istovremeno, odvojeno ili uzastopno davanje (a) navedenog farmaceutskog pripravka i (b) konjugat koji sadrži (i) polipeptid koji sadrži aminokiselinski slijed interleukina 15 ili njihovi derivati koji imaju najmanje 10% aktivnosti ljudskog IL-15 na indukciju proliferacije kit225 stanična linija i (ii) polipeptid koji sadrži aminokiselinski slijed suši domene IL-15Rα ili njihovi derivati koji imaju najmanje 10% aktivnosti vezivanja suši domene ljudskog IL-15Rα na humani IL-15, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid, i pri čemu je navedeno protutijelo antagonist PD-1/PD-L1/PD-L2, pri čemu se navedeno antitijelo antagonizira bilo vezanjem PD-1 receptora ili vezanjem PD-L1 ili PD-L2 liganda.
3. Farmaceutski pripravak za uporabu u liječenju raka prema zahtjevu 2 ili kombinirani farmaceutski pripravak prema zahtjevu 1, prilagođen za istovremeno, odvojeno ili sekvencijalno davanje za uporabu u liječenju raka kod subjekta.
4. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da: a) konjugat se daje injekcijom u dozi od 60 µg/kg ili manje, poželjno u dozi od 10 µg/kg ili manje, a najpoželjnije u dozi od 5 µg/kg ili manje; i b) antitijelo koje antagonizira imunološki put je uključeno u inhibiciju aktivacije T stanica, ili se njegov fragment daje injekcijom u dozi od 500 µg/kg ili manje, poželjno u dozi od 100 µg/kg ili manje, a najpoželjnije u dozi od 50 µg/kg ili manje.
5. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 4, naznačen time, da je spomenuto antitijelo antagonist PD-1/PD-L1.
6. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time, da navedeni derivat interleukina 15 ima najmanje 25% aktivnosti humanog interleukina-15 na indukciju proliferacije stanične linije kit225, poželjnije najmanje 50%, ili ima aminokiselinsku sekvencu koja ima postotak identiteta od najmanje 92,5% s aminokiselinskom sekvencom odabranom u grupi koja se sastoji od SEQ ID n°: 1, SEQ ID n°: 2 i SEQ ID nº: 3, po mogućnosti od najmanje 96% i poželjnije najmanje 98,5% ili najmanje 99%.
7. Farmaceutski pripravak ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 6, naznačen time, da navedeni derivat suši domene IL-15Rα ima najmanje 25%, poželjnije najmanje 50% vezivne aktivnosti suši domene ljudskog IL-15Rα, ili ima aminokiselinsku sekvencu koja ima postotak identičnosti od najmanje 92% sa aminokiselinskom sekvencom odabranom u grupi koja se sastoji od SEQ ID n°: 4, SEQ ID n°: 5, SEQ ID n°: 6, SEQ ID n°: 7, SEQ ID n°: 8 i SEQ ID n°: 9, poželjno najmanje 96%, a poželjnije najmanje 98%.
8. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da je spomenuto antitijelo izabrano između antagonista PD-1 / PD-L1 i PD-1 / PD-L2, poželjno nivolumaba, Merck 3745, CT-01 1, lambrolizumaba, AMP514, MDX-1 105 ili YW243.55.S70.
9. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 8, naznačen time što su polipeptidi (i) i (ii) konjugata kovalentno povezani u fuzijskom proteinu.
10. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 9, naznačen time, da navedeni interleukin 15 ima aminokiselinsku sekvencu SEQ ID n°: 1.
11. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 10, naznačen time što suši domena IL-15Rα ima aminokiselinsku sekvencu SEQ ID n°: 4.
12. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 11, naznačen time da konjugat ima sekvencu SEQ ID n°: 16 ili SEQ ID n°: 17.
HRP20192174TT 2013-08-08 2019-12-02 Kombinirani farmaceutski pripravak HRP20192174T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003964 2013-08-08
PCT/EP2014/002182 WO2015018529A1 (en) 2013-08-08 2014-08-08 Combined pharmaceutical composition
EP14761281.6A EP3030262B1 (en) 2013-08-08 2014-08-08 Combined pharmaceutical composition

Publications (1)

Publication Number Publication Date
HRP20192174T1 true HRP20192174T1 (hr) 2020-03-06

Family

ID=48951300

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192174TT HRP20192174T1 (hr) 2013-08-08 2019-12-02 Kombinirani farmaceutski pripravak

Country Status (17)

Country Link
US (3) US20160184399A1 (hr)
EP (2) EP3030262B1 (hr)
JP (3) JP6794255B2 (hr)
KR (2) KR20220148304A (hr)
CN (1) CN105579062A (hr)
CA (1) CA2920539C (hr)
CY (1) CY1122465T1 (hr)
DK (1) DK3030262T3 (hr)
ES (1) ES2760249T3 (hr)
HR (1) HRP20192174T1 (hr)
HU (1) HUE046964T2 (hr)
LT (1) LT3030262T (hr)
PL (1) PL3030262T3 (hr)
PT (1) PT3030262T (hr)
RS (1) RS59756B1 (hr)
SI (1) SI3030262T1 (hr)
WO (1) WO2015018529A1 (hr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2911A (en) 2005-12-02 2014-05-31 Sinai School Medicine Chimeric Viruses presenting non-native surface proteins and uses thereof
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
JP6794255B2 (ja) * 2013-08-08 2020-12-02 サイチューン ファーマ 組合せ医薬組成物
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
CN115058395A (zh) 2015-06-25 2022-09-16 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
EP3350205A1 (en) * 2015-09-16 2018-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
US20210000921A1 (en) * 2016-01-11 2021-01-07 Flagship Pioneering Innovations V. Inc. Methods and compositions for modulating thymic function
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2017201352A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
JP7114490B2 (ja) * 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
AU2017305335B2 (en) * 2016-08-01 2021-11-18 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
EP3526241A1 (en) 2016-10-14 2019-08-21 Xencor, Inc. Il15/il15r heterodimeric fc-fusion proteins
CA3067603A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
CN111432836A (zh) 2017-09-05 2020-07-17 转矩医疗股份有限公司 治疗性蛋白质组合物及其制备和使用方法
EP3727146A4 (en) * 2017-12-19 2021-10-06 Blaze Bioscience, Inc. CELL PENETRATION PEPTIDE TUMOR AND IMMUNO-ONCOLOGY ADDRESSING AGENT COMPLEXES AND METHODS OF USE
SG11202007518RA (en) 2018-02-28 2020-09-29 Pfizer Il-15 variants and uses thereof
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
CN113423734A (zh) 2018-10-12 2021-09-21 Xencor股份有限公司 靶向PD-1的IL-15/IL-15RαFC融合蛋白及其在联合疗法中的应用
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
AU2020279534A1 (en) * 2019-05-20 2021-11-11 Cytune Pharma IL-2/IL-15Rβy agonist dosing regimens for treating cancer or infectious diseases
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
AU2022246048A1 (en) 2021-03-26 2023-08-31 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2023278811A1 (en) 2021-07-01 2023-01-05 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024007020A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
JP3793693B2 (ja) 1998-12-23 2006-07-05 ファイザー インコーポレーテッド Ｃｔｌａ−４に対するヒトモノクローナル抗体
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7740845B2 (en) 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
EP3284753B1 (en) 2002-10-17 2019-06-05 Genmab A/S Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7858081B2 (en) 2004-02-27 2010-12-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) IL-15 mutants having agonists/antagonists activity
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
WO2006056875A1 (en) 2004-11-29 2006-06-01 Pharmacia & Upjohn Company Llc Thiazepine oxazolidinones as antibacterial agents
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES
US8124084B2 (en) 2005-05-17 2012-02-28 University Of Connecticut Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
CA2669921A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
NZ596237A (en) 2006-12-27 2012-07-27 Dana Farber Cancer Inst Inc Compositions and methods for the treatment of infections and tumors
WO2008116219A2 (en) 2007-03-22 2008-09-25 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
NZ703668A (en) * 2007-06-27 2016-07-29 Us Sec Dep Of Health And Human Services Complexes of il-15 and il-15ralpha and uses thereof
EA201000910A1 (ru) 2007-11-30 2011-04-29 Бристоль-Мейерз Сквибб Компани Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2408818A1 (en) 2009-03-17 2012-01-25 Université de la Méditerranée Btla antibodies and uses thereof
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
PL2691112T3 (pl) 2011-03-31 2018-09-28 Merck Sharp & Dohme Corp. Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2014066527A2 (en) * 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP6794255B2 (ja) * 2013-08-08 2020-12-02 サイチューン ファーマ 組合せ医薬組成物

Also Published As

Publication number Publication date
RS59756B1 (sr) 2020-02-28
US20220168395A1 (en) 2022-06-02
JP2019189638A (ja) 2019-10-31
WO2015018529A1 (en) 2015-02-12
HUE046964T2 (hu) 2020-04-28
JP2022091985A (ja) 2022-06-21
LT3030262T (lt) 2020-03-10
CY1122465T1 (el) 2021-01-27
ES2760249T3 (es) 2020-05-13
PL3030262T3 (pl) 2020-07-27
CA2920539C (en) 2024-01-02
KR20220148304A (ko) 2022-11-04
JP2016527286A (ja) 2016-09-08
US20220202904A1 (en) 2022-06-30
KR20160040632A (ko) 2016-04-14
EP3659622A1 (en) 2020-06-03
SI3030262T1 (sl) 2020-03-31
EP3030262A1 (en) 2016-06-15
DK3030262T3 (da) 2019-12-02
US20160184399A1 (en) 2016-06-30
CA2920539A1 (en) 2015-02-12
JP6794255B2 (ja) 2020-12-02
EP3030262B1 (en) 2019-10-09
CN105579062A (zh) 2016-05-11
PT3030262T (pt) 2019-12-11
KR102457731B1 (ko) 2022-10-21

Similar Documents

Publication Publication Date Title
HRP20192174T1 (hr) Kombinirani farmaceutski pripravak
JP2016527286A5 (hr)
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
HRP20231437T1 (hr) Il-15 i il-15ralpha sushi domena na temelju modulokina
HRP20210122T1 (hr) Protutijela usmjerena protiv programirane smrti-1 (pd-1)
Eggermont et al. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies
PH12020550929A1 (en) Bicyclic peptide ligands specific for epha2
EA201891074A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака
WO2016022994A3 (en) High affinity pd-1 agents and methods of use
WO2014089169A4 (en) Immunotherapy with binding agents
HRP20231570T1 (hr) Peptid za uporabu u imunoterapiji protiv nesitnostaničnog raka pluća i sitnostaničnog raka pluća
EA201290123A1 (ru) Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
BRPI1013877A2 (pt) Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
HRP20220717T1 (hr) Modificirani pripravci mrna
RS54233B1 (en) PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
HRP20200085T1 (hr) Topljivi cd33 za liječenje mijelodisplastičnih sindroma (mds)
GB201201314D0 (en) Composition
BR112018004078A2 (pt) composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo
WO2012140647A3 (en) Albumin binding probes and drug conjugates thereof
MX2019000135A (es) Anticuerpos anti-transicion mesenquimal-epitelial (met) y usos de los mismos.
Jung et al. Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells
JP2016523558A5 (hr)
MX2019014504A (es) Inmunoglobulinas de union a agrecano.